申请人:University of Florida
公开号:US04727079A1
公开(公告)日:1988-02-23
A brain-specific dopaminergic response is elicited in a patient in need of such treatment, e.g., a patient afflicted with Parkinson's disease of hyperprolactinemia, by administering thereto a therapeutically effective amount of preferably catechol protected dopamine tethered to a reduced, blood-brain barrier penetrating lipoidal form [D-DHC] of a dihydropyridine.revreaction.pyridinium salt type redox carrier, e.g., 1,4-dihydrotrigonelline. Oxidation of the dihydropyridine carrier moiety in vivo to the ionic pyridinium salt type dopamine/carrier entity [D-QC].sup.+ prevents elimination thereof from the brain, while elimination from the general circulation is accelerated, resulting in significant and prolongedly sustained brain-specific dopaminergic activity.
一种特定于大脑的多巴胺反应被引发,以治疗有需要的患者,例如,患有帕金森病或垂体高泌乳素血症的患者,通过向其投予一定量的治疗有效的優選的優選的優選的優選的優選的多巴胺,其被连接到一种降低的,穿透血脑屏障的脂质形式[D-DHC]的二氢吡啶盐型氧化还原载体,例如,1,4-二氢三甲基咖啡碱。体内二氢吡啶载体基团的氧化形成离子型吡啶盐型多巴胺/载体实体[D-QC].sup.+,防止其从大脑中排泄,同时加速其从一般循环中的排泄,导致显著且持续时间较长的大脑特异性多巴胺活性。